TG Therapeutics Reports Positive UNITY-NHL Phase 2b Clinical Trial Results

published 9:05 pm ET November 1st, 2019

On October 28, TG Therapeutics, Inc. (TGTX) reported positive results from the UNITY-NHL Phase 2b pivotal trial. The study evaluates umbralisib monotherapy in patients with relapsed/refractory follicular lymphoma. The Follicular Lymphoma cohort met the primary endpoint of 40-50% overall response rate (ORR). The therapy was well tolerated and had a safety profile consistent with previous reports.

 

Jet Equities issued an alert at 7:00am. The last trade took place at 4:31 pm on the previous day for $5.78. The stock price spiked towards $6.50 at the market open on October 28 and continued to move higher over the next four trading days. TG Therapeutics closed at $7.08 on November 1 for a five-day gain of 22.5%.

 

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

Subscribe here if you would like to start receiving these signals in real-time and start trading!